Telescope enters development deal with AGI Group

Executive Summary

• Telescope Innovations Corp. has entered into a development and collaboration agreement with AGI SDA (part of the AGI Group) to develop next-generation automation- and AI-ready chemical reactor technology.
• The partnership aims to integrate Telescope’s sample capture and transfer expertise with AGI’s automated laboratory and pilot plant reactor systems, targeting the creation of an integrated commercial product.
• The collaboration is part of a broader initiative involving six major biopharmaceutical companies, with the goal of advancing "self-driving labs" (SDLs) that combine robotic automation, real-time analysis, and AI to accelerate R&D.

Key Details

• Agreement Type: Development and collaboration agreement.
• Parties: Telescope Innovations Corp. and AGI Group’s synthesis, digitization and automation program (AGI SDA).
• Strategic Context: The collaboration is spearheading a broader effort involving six major biopharmaceutical companies focused on developing this technology for eventual commercial offering.
• Technology Integration:
  • Telescope will integrate its market-proven technology for capturing high-quality, representative samples from chemical reactions and automatically transferring them to downstream instruments.
  • This expertise is evidenced by the commercial success of its flagship product, DirectInject-LC.
  • The integration couples automated reaction execution with real-time, hands-free analysis within AGI’s reactor system.
• Market Positioning: The partnership strengthens Telescope’s position as a market leader in automating the sampling and analysis of chemical reactions.
• Self-Driving Labs (SDLs):
  • The technology is designed to fit into SDLs, which use robotic automation, real-time process analysis, and AI to autonomously execute chemistry experiments.
  • Telescope has already deployed two such systems for international biopharmaceutical clients, including Pfizer.
• AGI Group Background:
  • Headquartered in Japan with over 1,000 employees globally.
  • AGI SDA is an innovator in automated laboratory and pilot plant reactors and related control instrumentation.
• Product Timeline: AGI Group plans to release its state-of-the-art Synto platform mid-2027 as part of this long-term partnership.

Notable Quotes

• Henry Dubina, CEO of Telescope Innovations: "Global players in lab instrumentation and automation, like AGI SDA, recognize Telescope's technology advantages and are actively seeking to work with us on the future of intelligent chemistry. We're excited to continue pushing the envelope on tech that enables faster, lower-cost R&D for chemical process deployment, biopharmaceutical development and advanced manufacturing."
• Francis Van der Eycken, Chief Strategy Officer, AGI Group/Managing Director, AGI SDA: "Telescope Innovations is selected as our strategic partner for the development of the sampling platform and robotics integration. AGI Group views this collaboration agreement as the start of a long-term partnership to continue developing novel and impactful solutions in this space, together with the state-of-the-art Synto platform, planned to be released mid-2027."